Adial Pharmaceuticals, Inc (ADIL): Price and Financial Metrics
GET POWR RATINGS... FREE!
ADIL Stock Price Chart Interactive Chart >
ADIL Price/Volume Stats
| Current price | $2.70 | 52-week high | $4.00 |
| Prev. close | $2.70 | 52-week low | $1.14 |
| Day low | $2.66 | Volume | 40,200 |
| Day high | $2.76 | Avg. volume | 466,237 |
| 50-day MA | $2.35 | Dividend yield | N/A |
| 200-day MA | $2.11 | Market Cap | 48.89M |
Adial Pharmaceuticals, Inc (ADIL) Company Bio
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic agents for the treatment of alcohol use disorders in the United States. Its lead product is AD04, a selective serotonin-3 antagonist that has completed Phase IIb clinical trials for the treatment of nausea and emesis. The company was founded in 2010 and is based in Charlottesville, Virginia.
Latest ADIL News From Around the Web
Below are the latest news stories about Adial Pharmaceuticals Inc that investors may wish to consider to help them evaluate ADIL as an investment opportunity.
Adial Pharmaceuticals Comments on Article in ‘The Atlantic,’ Highlighting the Second Pandemic of AddictionCHARLOTTESVILLE, Va., June 07, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, commends Kate Julian and The Atlantic for highlighting the major crisis facing our society in her article America Has a Drinking Problem. The article highlights the complexity of the factors driving alcohol use and its per |
Adial Announces Funding of Management-Led $2,100,000 Above Market Private Placement at $3.00 Per ShareCHARLOTTESVILLE, Va., June 03, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that it has completed the $2,100,000 private placement of 700,001 shares of common stock at a price of $3.00 per share (the “Shares”) on June 1, 2021. The private placement investors included Bespoke Growth |
Adial Pharma Seeks To Treat The Pandemic Of AddictionAs COVID vaccines spread globally, many are returning to pre-pandemic life with routine and socialization. But what about the other pandemics? The problems of mental health and drug addiction have been prevalent in our society long before the coronavirus but were gravely exacerbated over the past year to the point that they might be called a “second pandemic.” The economic struggle combined with losing loved ones, healthcare, career opportunities, shelter, other disruptions to quality of life have caused some to turn to drugs and alcohol for comfort or an escape. Those who were previously addicts are no doubt struggling, but more and more names get added to the list daily. It’s been predicted that alcohol use increased globally by 75% over the past 12 months. So how does our society tac... |
Adial Schedules Town Hall to Discuss Positive Updates Regarding Pharmaceutical Pipeline and Business ExpansionCHARLOTTESVILLE, Va., Feb. 26, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial”), a clinical-stage biopharmaceutical company focused on the development of treatments for addictions, today announced that it will host a Town Hall at 1 P.M., Eastern Time on Thursday, March 18, 2021. Information for shareholders interested in attending will be available at the Company’s Investors section of the website: https://ir.adialpharma.com/ About Adial Pharmaceuticals, Inc. Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of treatments for addictions. The Company’s lead investigational new drug product, AD04, is a genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Di... |
Adial Receives $1.425 Million in Net Proceeds from Exercise of WarrantsCHARLOTTESVILLE, Va., Feb. 26, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of treatments for addictions, today announced the exercise of 712,500 warrants from its June 2020 financing for net proceeds to the company of $1,425,000. About Adial Pharmaceuticals, Inc. Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of treatments for addictions. The Company’s lead investigational new drug product, AD04, is a genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD) and is currently being investigated in the Company’s landmark ONWARD™ pivotal Phase 3 clinical... |
ADIL Price Returns
| 1-mo | 31.71% |
| 3-mo | 5.06% |
| 6-mo | 39.90% |
| 1-year | 82.43% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | 58.82% |
| 2020 | -29.46% |
| 2019 | -52.93% |
| 2018 | N/A |
| 2017 | N/A |
| 2016 | N/A |
Loading social stream, please wait...